What is PEG-MGF?
PEG-MGF refers to a pegylated version of mechano growth factor, the IGF-1Ec E-domain peptide discussed in muscle and repair biology. PEGylation is intended to extend exposure compared with an unmodified peptide fragment. [1][2][3]
The evidence problem is molecule specificity. Mechano growth factor and IGF-1 splice-variant literature can support biological plausibility, but it does not automatically validate commercial PEG-MGF products or injectable protocols. [1][2][3]
The name is often used in performance catalogs. That market usage needs separation from the peer-reviewed MGF literature, product identity, and anti-doping status. [1][2][3]
What PEG-MGF is investigated for
PEG-MGF evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Muscle growth and training recovery
Injectable
Muscle growth and training recovery
Injectable
Musculoskeletal tissue repair
Injectable
Musculoskeletal tissue repair
Injectable
Evidence snapshot
Overall confidence
PEG-MGF remains a preclinical muscle-repair rationale rather than a proven performance peptide. The main gaps are product-specific human pharmacology, outcome data, and safety evidence. [1][2][3][4]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
No controlled human PEG-MGF outcome evidence establishes muscle growth, repair, or training adaptation. Reader-facing confidence therefore depends on indirect MGF and IGF-1Ec literature. [1][2][3][4]
Animal / preclinical
MGF and IGF-1Ec studies support repair and regeneration plausibility in experimental systems. PEGylated-product translation is not settled. [1][2][3][4]
Mechanism support
MGF-related peptides are discussed around local tissue responses to mechanical stress and muscle-cell repair behavior. The peptide concept is mechanistic, not outcome-proven. [1][2][3][4]
Forms & administration
PEG-MGF is tracked as an injectable growth-factor-adjacent research peptide. Post-training protocol patterns are separate from prescription IGF or GH products. [8][1][2]
Dosing & protocols
The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.
Typical Range
Common injectable protocols usually use 200-400 mcg per dose. [8][1][2]
Frequency
Common injectable schedules use 2-3 doses weekly rather than daily indefinite exposure. [8][1][2]
Timing Considerations
Post-workout timing is the common anchor; off-day timing is less standardized than training-day logging. [8][1][2]
Cycle Length
Common injectable blocks run 4-6 weeks before comparing training load, soreness, body composition, and adverse-effect notes. [8][1][2]
What to expect
First 1-2 weeks
Post-workout injectable PEG-MGF use may align with changes in muscle pump, soreness between sessions, and perceived recovery from loaded training. [1][2][3][4][8]
Weeks 4-6
Injectable post-training blocks may show as clearer strength trends, training volume, soreness patterns, and limb-measurement changes. [1][2][3][4][8]
After stopping
Recovery and hypertrophy signals after injectable PEG-MGF depend mostly on whether training load, nutrition, and sleep remain consistent. [1][2][3][4][8]
Safety profile
PEG-MGF safety is driven by growth-factor biology and injectable product identity rather than a mature human side-effect profile. [10]
Who PEG-MGF is not for
Route-specific avoid and medical-review notes:
Drug & supplement interactions
Documented interactions are separated from theoretical or route-specific cautions.
Theoretical interactions
- IGF / GH products
IGF analogs, somatropin, GH secretagogues, or MGF variants can stack growth-factor exposure and edema signals; this is a theoretical pathway caution. [10]
- Anabolic hormones
Testosterone or anabolic agents can compound muscle-growth claims and fluid-retention signals; this is a theoretical pathway caution. [10]
- Performance stacks
Performance stacks that combine multiple prohibited growth-factor products can add regulatory and product-quality uncertainty; this is a product-quality caution. [10]
Regulatory status
United States
In the U.S. as of 2026-06-21, PEG-MGF is not FDA-approved for the reviewed injectable route. FDA compounding safety-risk materials flag this substance or close naming variant, so the 503A row should be read as a safety-risk bucket, not approval. [14][8][9][12][13]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Injectable | Not Approved PEG-MGF is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [8][9][12][13] | Flagged FDA safety-risk materials flag PEG-MGF with significant immunogenicity, peptide-impurity, API-characterization, and missing human-exposure concerns. This is a 503A compounding safety-risk bucket, not FDA drug approval. [14][8][9][12][13] |
Injectable
International
EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets. [15][16][17][18]
Sports & competition
WADA S2 applies to growth factors and IGF-axis products; tested athletes should treat PEG-MGF as prohibited unless a valid TUE or anti-doping review applies. [10][8][9][12][13]
How it works
PEG-MGF sits in the mechano-growth-factor story: an IGF-1 splice-variant E-domain concept tied to mechanical stress, muscle-cell behavior, cartilage biology, and repair signaling. In plain terms, the proposed target is local regeneration biology after tissue strain. [1][2][3][4]
PEGylation changes the mechanism question because it can extend exposure and alter immune or product-quality risk. Evidence for parent MGF or synthetic E-domain peptides does not prove that an injectable PEGylated product has the same benefit-risk balance in humans. Sterility and peptide aggregation risk are also part of the route-specific interpretation. [1][2][3][4]
Research gaps & open questions
What the current literature has not yet settled about PEG-MGF:
Common questions
Is PEG-MGF FDA-approved?
Does MGF evidence prove PEG-MGF works?
Myths & misconceptions
History & discovery
PEG-MGF grew out of mechano-growth-factor work, where IGF-1 splice-variant biology was connected with mechanical load, muscle repair, cartilage, and regeneration. The PEGylated market product came later. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty. [1][2][3][4]
MGF and IGF-1Ec studies gave the peptide a repair-and-regeneration rationale across muscle, motor-neuron, and cartilage models. That history supports plausibility, not product-level human efficacy. [1][2][3][4]
PEG-MGF entered catalog use as a longer-exposure version of MGF-style signaling. PEGylation changed the route and safety question, so parent-MGF findings do not settle injectable PEG-MGF outcomes. [1][2][3][4]
10 studies
Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration.
Endocrinology, 2010 Mar. review.
Biological activity of the e domain of the IGF-1Ec as addressed by synthetic peptides.
Hormones (Athens), 2014 Apr-Jun. review.
Mechano-growth factor, an IGF-I splice variant, rescues motoneurons and improves muscle function in SOD1(G93A) mice.
Exp Neurol, 2009 Feb. animal.
The role of mechano growth factor in chondrocytes and cartilage defects: a concise review.
Acta Biochim Biophys Sin (Shanghai), 2023 May 12. review.
Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages.
Mech Ageing Dev, 2011 Apr. in vitro.
Mechano-growth factor regulates periodontal ligament stem cell proliferation and differentiation through Fyn-RhoA-YAP signaling.
Biochem Biophys Res Commun, 2024 Nov 12. in vitro.
Mechano-growth factor E-domain modulates cardiac contractile function through 14-3-3 protein interactomes.
Front Physiol, 2022. review.
Drugs@FDA/openFDA query for PEG-MGF
U.S. Food and Drug Administration. database query.
Compounding and the FDA: Questions and Answers
U.S. Food and Drug Administration. official guidance.
The 2026 List of Prohibited Substances and Methods
World Anti-Doping Agency. regulatory.